查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589208

重症加护诊断市场：通过测试、最终用户 - 2025-2030 年全球预测

Critical Care Diagnostics Market by Test (Coagulation Testing, Flow Cytometry, Hematology), End-User (Emergency Rooms, Intensive Care Units, Operation Rooms) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年重症加护诊断市场价值为12.3亿美元，预计到2024年将达到14.5亿美元，复合年增长率为17.97%，预计到2030年将达到39.1亿美元。

重症加护诊断涉及使用技术工具和设备来诊断危及生命的病症并监测重症加护室（例如 ICU 和急诊科）的治疗情况。该领域包括广泛的测试和设备，包括血液分析仪、诊断影像和分子诊断设备，这对于快速决策和有效管理严重和伤害至关重要。慢性和急性疾病的盛行率不断上升，加上世界人口的老化，增加了对快速、准确的诊断解决方案的需求，证明了对重症加护诊断的需求。其应用范围从脓毒症和肺炎的早期检测到监测重要器官功能。最终用户主要包括医院、诊所和诊断中心，他们不断需要高效、可靠的诊断选项。

主要市场统计
基准年[2023] 12.3亿美元
预测年份 [2024] 14.5亿美元
预测年份 [2030] 39.1亿美元
复合年增长率（%） 17.97%

影响该市场的关键成长要素包括诊断工具的技术进步、医疗保健成本的上升、对以患者为中心的护理的日益关注，以及用于自动化诊断和个人化治疗策略的人工智慧和机器学习的整合机会。由于医疗基础设施的改善和医疗服务投资的增加，新兴国家提供了潜在的成长机会。然而，先进诊断设备的高成本、熟练劳动力的缺乏以及严格的法律规范等挑战可能会阻碍市场成长。不同诊断设备之间的互通性问题也产生了限制，需要标准化工作。

需要开拓的创新领域包括开发可携式和照护现场诊断设备，以显着减轻医疗机构的负担并提高可及性。对非侵入性诊断技术和远端医疗整合等数位健康解决方案的探索预计将提高市场渗透率。市场竞争激烈，技术变革迅速，创新不断。追求卓越的公司应专注于建立策略伙伴关係、投资研发并扩大产品系列，以满足重症加护诊断不断变化的需求。

市场动态：快速发展的重症加护诊断市场的关键市场洞察

供应和需求的动态交互作用正在改变重症加护诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界老年人口增加和慢性病盛行率
    • 快速诊断和治疗的需求不断增长
    • 资料管理和电子健康记录(EHR) 连接性的成长
  • 市场限制因素
    • 诊断工具高成本
  • 市场机会
    • 重症加护诊断的政府活动和引进支持
    • 增加诊断设备和实验室之间的远端通讯
  • 市场挑战
    • 缺乏熟练的专业人员

波特五力：驾驭重症加护诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解重症加护诊断市场的外部影响

外部宏观环境因素在塑造重症加护诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解重症加护诊断市场的竞争格局

对重症加护诊断市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV重症加护诊断市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估重症加护诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了重症加护诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对重症加护诊断市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地老年人口不断增加和慢性病盛行率
      • 对快速诊断和治疗的需求不断增加
      • 改善资料管理和与电子健康记录 (EHR) 的连接
    • 抑制因素
      • 诊断工具高成本
    • 机会
      • 重症加护诊断的政府活动和实施支持
      • 增加诊断和实验室之间的远端通讯
    • 任务
      • 缺乏熟练的专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章重症加护诊断市场测试

  • 血液凝固检验
  • 流式细胞技术
  • 血液学
  • 免疫蛋白
  • 微生物与感染疾病
  • 日用化学和特殊化学

第七章重症加护诊断市场：依最终使用者分类

  • 急诊室
  • 加护病房
  • 手术室

第八章美洲重症加护诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太重症加护诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的重症加护诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Becton, Dickinson & Company
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • HORIBA, Ltd.
  • Johnson and Johnson Service, Inc.
  • Medcaptain Medical Technology Co., Ltd
  • Medtronic PLC
  • Omron Corporation
  • Roche Diagnostics Ltd.
  • Sysmex Corporation
  • WerfenLife, SA
Product Code: MRR-807A20B5CC5E

The Critical Care Diagnostics Market was valued at USD 1.23 billion in 2023, expected to reach USD 1.45 billion in 2024, and is projected to grow at a CAGR of 17.97%, to USD 3.91 billion by 2030.

Critical care diagnostics involves the use of technological tools and equipment to diagnose life-threatening conditions and monitor treatment in critical care settings, such as ICUs and emergency departments. This field encompasses a wide range of tests and devices, including blood analyzers, imaging equipment, and molecular diagnostics, which are essential for swift decision-making and effective management of severe illnesses or injuries. The necessity of critical care diagnostics is underscored by the increasing prevalence of chronic and acute medical conditions, coupled with the aging global population, which heightens the demand for rapid and accurate diagnostic solutions. Their application spans from early detection of sepsis and pneumonia to monitoring vital organ functions, thereby enhancing patient care and outcomes. End users primarily include hospitals, clinics, and diagnostic centers, which continually seek efficient and reliable diagnostic options.

KEY MARKET STATISTICS
Base Year [2023] USD 1.23 billion
Estimated Year [2024] USD 1.45 billion
Forecast Year [2030] USD 3.91 billion
CAGR (%) 17.97%

Key growth factors influencing this market include technological advancements in diagnostic tools, increasing healthcare expenditure, and a heightened focus on patient-centric care, highlighting opportunities in the integration of artificial intelligence and machine learning for automated diagnostics and personalized treatment strategies. Emerging economies present potential growth opportunities due to improving healthcare infrastructure and increased investments in healthcare services. However, challenges like high costs of advanced diagnostic devices, a lack of skilled personnel, and stringent regulatory frameworks can impede market growth. Limitations also arise from interoperability issues of different diagnostic devices, necessitating standardization efforts.

Innovation areas ripe for exploration include the development of portable and point-of-care diagnostic devices, which can significantly alleviate burdens on healthcare facilities and improve accessibility. Research into non-invasive diagnostic techniques and digital health solutions, such as telemedicine integration, holds promise for enhanced market penetration. The market is competitive, characterized by rapid technological changes and continuous innovation. Companies looking to excel should focus on forming strategic partnerships, investing in R&D, and expanding their product portfolios to cater to the evolving needs of critical care diagnostics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Critical Care Diagnostics Market

The Critical Care Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population worldwide and prevalence of chronic diseases
    • Increasing demand for rapid diagnosis and treatment
    • Growth in data management and connectivity to Electronic Health Record (EHR)
  • Market Restraints
    • High cost of diagnostics tools
  • Market Opportunities
    • Government activities and support for implementing critical care diagnostics
    • Rising remote communications between diagnostics and laboratories
  • Market Challenges
    • Lack of Skilled Professionals

Porter's Five Forces: A Strategic Tool for Navigating the Critical Care Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Critical Care Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Critical Care Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Critical Care Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Critical Care Diagnostics Market

A detailed market share analysis in the Critical Care Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Critical Care Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Critical Care Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Critical Care Diagnostics Market

A strategic analysis of the Critical Care Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Critical Care Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Bayer Healthcare AG, Becton, Dickinson & Company, Danaher Corporation, EKF Diagnostics Holdings PLC, F. Hoffmann-La Roche AG, General Electric Company, HORIBA, Ltd., Johnson and Johnson Service, Inc., Medcaptain Medical Technology Co., Ltd, Medtronic PLC, Omron Corporation, Roche Diagnostics Ltd., Sysmex Corporation, and WerfenLife, S.A..

Market Segmentation & Coverage

This research report categorizes the Critical Care Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test, market is studied across Coagulation Testing, Flow Cytometry, Hematology, Immunoproteins, Microbial & Infectious Diseases, and Routine & Special Chemistry.
  • Based on End-User, market is studied across Emergency Rooms, Intensive Care Units, and Operation Rooms.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population worldwide and prevalence of chronic diseases
      • 5.1.1.2. Increasing demand for rapid diagnosis and treatment
      • 5.1.1.3. Growth in data management and connectivity to Electronic Health Record (EHR)
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diagnostics tools
    • 5.1.3. Opportunities
      • 5.1.3.1. Government activities and support for implementing critical care diagnostics
      • 5.1.3.2. Rising remote communications between diagnostics and laboratories
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Skilled Professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Critical Care Diagnostics Market, by Test

  • 6.1. Introduction
  • 6.2. Coagulation Testing
  • 6.3. Flow Cytometry
  • 6.4. Hematology
  • 6.5. Immunoproteins
  • 6.6. Microbial & Infectious Diseases
  • 6.7. Routine & Special Chemistry

7. Critical Care Diagnostics Market, by End-User

  • 7.1. Introduction
  • 7.2. Emergency Rooms
  • 7.3. Intensive Care Units
  • 7.4. Operation Rooms

8. Americas Critical Care Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Critical Care Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Critical Care Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Bayer Healthcare AG
  • 3. Becton, Dickinson & Company
  • 4. Danaher Corporation
  • 5. EKF Diagnostics Holdings PLC
  • 6. F. Hoffmann-La Roche AG
  • 7. General Electric Company
  • 8. HORIBA, Ltd.
  • 9. Johnson and Johnson Service, Inc.
  • 10. Medcaptain Medical Technology Co., Ltd
  • 11. Medtronic PLC
  • 12. Omron Corporation
  • 13. Roche Diagnostics Ltd.
  • 14. Sysmex Corporation
  • 15. WerfenLife, S.A.

LIST OF FIGURES

  • FIGURE 1. CRITICAL CARE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CRITICAL CARE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CRITICAL CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CRITICAL CARE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRITICAL CARE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRITICAL CARE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COAGULATION TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY IMMUNOPROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY MICROBIAL & INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY ROUTINE & SPECIAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY EMERGENCY ROOMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY INTENSIVE CARE UNITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY OPERATION ROOMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. CRITICAL CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. CRITICAL CARE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023